Viamet Receives Orphan Drug Designation from the FDA for VT-1598 for the Treatment of Coccidioidomycosis

Viamet Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted orphan drug designation to VT-1598 for the treatment of coccidioidomycosis, or Valley Fever. VT-1598 is a selective, orally available inhibitor of fungal CYP51 that has demonstrated high potency in preclinical studies against Coccidioides species, the fungal pathogens responsible for Valley Fever.